+ Watch VPHM
on My Watchlist
A biopharmaceutical company dedicated to the development and commercialization of products that address serious infectious diseases, with a focus on products used by physician specialists or in hospital settings.
2008 4th qtr missed estimates which was disappointing, however forward looking still is favorable. In the 4th qtr, they took a one time write down of $2.3 million for closing their corporate headquarters. While many firms unwisely cut R&D expenses when in troubled times, ViroPharma actually increased 4th qtr R&D expenses by 76% which should help fill pipelines to replace Vancocin if and when it goes generic at some point. 2009 guidance did not put revenues in for Cinryze due to uncertainty. This is an upside with high probablity. They continue to generate strong free cash flows.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions